查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
三陰性乳癌市場:KOL的洞察
市場調查報告書
商品編碼
1719510

三陰性乳癌市場:KOL的洞察

KOL Insight - Breast Cancer - Triple Negative
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

這份綜合報告提供了來自美國和歐洲的12位 KOL（關鍵意見領袖）對三陰性乳癌 (TNBC) 治療的現狀和未來的寶貴見解。本報告研究了臨床試驗對 Keytruda 採用和意義的影響，評估了數據法的變革潛力，並考慮了 sacituzumab-tilmotecan 等新興療法的作用。本報告指出了三陰性乳癌治療中尚未滿足的重大需求，並預測了未來五年治療演算法將如何變化。詳細了解已上市和正在研發的療法及其臨床數據以及重塑治療方法的潛力。

主要問題解答

  • 1.針對不同類別的 TNBC 患者和治療線，可選擇的治療方法有哪些？
  • 2.標靶治療在療效、耐受性和易用性方面有何比較？
  • 3.哪些臨床試驗可能對未來的處方趨勢產生最大影響？
  • 4.一種藥物需要具備哪些特徵才能成為同類藥物中的首選治療藥物？
  • 5.目前正在開發和籌備中的產品將如何影響未來的治療偏好和方法？
  • 6.新療法必須達到哪些療效和耐受性終點才能有效競爭？
  • 7.哪些正在研發的療法最有前景？它們將如何影響市場上的現有企業？
  • 8.預期不同患者族群的治療前景將如何改變？

領導品牌

  • Lynparza
  • Talzenna
  • Tecentriq
  • Keytruda
  • Trodelvy
  • Enhertu
  • Bavencio
  • Zejula
  • Datroway
  • veliparib
  • sacituzumab tirumotecan

部分與會專家名單

  • 杜克大學醫學教授、放射腫瘤學系教授、北卡羅萊納州達勒姆市杜克大學乳房臨床研究中心共同主任。
  • 耶魯大學醫學院耶魯癌症中心教授。
  • 匹茲堡大學醫學院教授。
  • 維也納醫科大學（奧地利維也納）醫學副教授和腫瘤內科醫師。
  • 義大利摩德納大學醫院腫瘤學和血液學系腫瘤學副教授；乳房腫瘤科專家。
  • 英國牛津癌症中 心腫瘤內科顧問醫師與英國牛津大學資深臨床研究員。

方法論：

《治療趨勢》報告是透過對全球領先的關鍵意見領袖 (KOL) 進行深入訪談，了解主要疾病領域的當前和未來治療前景而編寫的。 KOL 是根據嚴格的篩選標準精心挑選出來的，包括全球聲譽、臨床專業知識和其在治療領域的影響力。每次訪談都遵循精心設計的討論指南。這些指南是與 KOL 合作開發的，並經過行業專家的同行評審，以確保問題全面且與當前市場動態相關。透過在每份報告發布後12個月的持續市場監測，我們及時提供來自 KOL 的重大新聞事件、市場變化和市場發展的更新。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥領域，為生物製藥專業人士和決策者提供深入、可行的見解。我們深厚的行業知識使我們能夠提供相關且有價值的見解，幫助我們的客戶了解新興趨勢並有效地解決複雜的挑戰。我們的報告以廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解為後盾，為您提供所需的準確性和可信度。獨家採訪和數據以及持續的市場監控使我們能夠全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域、包含 KOL 洞察和定量醫生調查的醫生情報以及行業專家對醫療事務、數位健康、銷售和營銷、市場准入和其他領域問題的看法，使您能夠做出更明智的、數據驅動的決策並在快速變化的行業中保持競爭力。

簡介目錄

This comprehensive report delves into the current and future landscape of triple-negative breast cancer (TNBC) treatments, offering valuable insights from 12 key opinion leaders (KOLs) across the US and Europe. It examines the influence of clinical trials on the adoption and significance of Keytruda, evaluates the transformative potential of Datroway, and considers the role of emerging therapies like sacituzumab tirumotecan. The report highlights significant unmet needs in TNBC treatment and anticipates shifts in treatment algorithms over the next five years. Gain a detailed understanding of both marketed and pipeline therapies, alongside their clinical data and potential to reshape therapeutic approaches.

Key Questions Answered:

  • 1. What is the treatment of choice for each TNBC patient segment and line of therapy?
  • 2. How do targeted therapies compare in terms of efficacy, tolerability, and ease of administration?
  • 3. Which clinical trials are most likely to impact future prescribing trends?
  • 4. What are the necessary attributes for a drug to become the preferred treatment in its category?
  • 5. How will current and pipeline products affect future treatment preferences and lines of therapy?
  • 6. What efficacy and tolerability endpoints must new therapies achieve to compete effectively?
  • 7. Which pipeline therapies hold the most promise and how will they influence existing market players?
  • 8. How is the treatment landscape expected to evolve across different patient segments?

Key Brands:

  • Lynparza
  • Talzenna
  • Tecentriq
  • Keytruda
  • Trodelvy
  • Enhertu
  • Bavencio
  • Zejula
  • Datroway
  • veliparib
  • sacituzumab tirumotecan

Partial List of Participating Experts:

  • Medical Professor of Radiation Oncology and Co-Director of the Breast Clinical Research Unit at Duke University, Durham, NC.
  • Professor of Medicine at Yale Cancer Center, Yale School of Medicine, New Haven, CT.
  • Professor of Medicine at the University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Associate Professor of Medicine, Consultant Medical Oncologist at the Medical University of Vienna, Vienna, Austria.
  • Associate Professor of Oncology, and Breast Oncology Specialist at the Department of Oncology and Haematology, University Hospital of Modena, Modena, Italy.
  • Consultant Medical Oncologist at the Oxford Cancer Centre and Senior Clinical Researcher at the University of Oxford, Oxford, UK.

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.